Letters to the EditorDOUBLE-BLIND TRIAL OF LITHIUM CARBONATE AND HALOPERIDOL IN HUNTINGTON'S CHOREA
References (8)
Lancet
(1973)Lancet
(1973)- et al.
Lancet
(1973) - et al.
Lancet
(1973)
Cited by (20)
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders
2010, Pharmacology and TherapeuticsCitation Excerpt :However, some other reports showed that lithium exerted no beneficial effects in HD patients (Aminoff & Marshall, 1974; Vestergaard et al., 1977). In some instances, lithium treatment even worsened motor and cognitive performance, particularly when used as the sole therapeutic agent (Carman et al., 1974; Leonard et al., 1974). Nonetheless, it should be noted that the number of patients included in those trials was small, and the duration of lithium treatment was also too short to assess the potential benefit of this drug.
Clinical Features and Care
2010, Blue Books of NeurologyCitation Excerpt :Physical and occupational therapies are sensible, but there are no controlled studies of benefit. Agents that block postsynaptic dopamine receptors (e.g., fluphenazine,143 haloperidol144) are generally effective in suppressing chorea, but treatment is often associated with nagging long-term risks of promoting superimposed tardive dyskinesia and the more immediate adverse effects of dysphoria, apathy, and bradykinesia. The so-called atypical antipsychotic drugs might be expected to lessen chorea; however, only clozapine has been subjected to short-term rigorous assessment and with weak results.145
A review of clinical trials of lithium in neurology
1984, Pharmacology, Biochemistry and BehaviorTherapeutic potential of mood stabilizers lithium and valproic acid: Beyond bipolar disorder
2013, Pharmacological ReviewsHuntington’s Disease—Update on Treatments
2017, Current Neurology and Neuroscience Reports